Brief: Medacta Receives FDA Approval For M-Vizion
May 13 (Reuters) - MEDACTA GROUP SA MOVE.S :
* SAID ON TUESDAY IT RECEIVED FDA APPROVAL FOR M-VIZION
FEMORAL
REVISION SYSTEM EXTENSION FOR HIP ARTHROPLASTY AND ITS LONG
HUMERAL DIAPHYSIS FOR SHOULDER JOINT REPLACEMENT
Source text for Eikon: ID:nEQ2Q9Vc0a
Further company coverage: MOVE.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))
Recent news on Medacta SA
See all newsBrief: Medacta Group Updates 2026 Guidance, Reiterates 2024-2027 Mid-Term Outlook
Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Brief: Medacta H1 Adjusted EBITDA EUR 97 Million
Switzerland's Medacta H1 revenue rises 9.7% in constant currency
Brief: Medacta H1 Revenue EUR 368 Million